Clinical Research · global
Hepatitis B gene-editing therapy shows sustained antiviral signals as PBGENE-HBV moves toward Phase 2
In an early trial, viral pregenomic RNA fell to undetectable levels in 11 of 12 evaluable patients, while liver biopsies also provided clues to the mechanism of action. But patients remain on antiviral medication, and whether control can be maintained after treatment withdrawal will be the key test in the next stage.
One challenge in treating chronic hepatitis B is that even after viral replication is suppressed, DNA that allows the virus to rebound may remain in liver cells. On November 5, Precision BioSciences announced Phase 1 data for its in vivo gene-editing therapy PBGENE-HBV, with blood and liver biopsy results showing antiviral activity. The company selected a dose for Phase 2 development based on these findings. However, these preliminary indicators do not establish that patients have been cured.
PBGENE-HBV targets covalently closed circular DNA (cccDNA), a form of viral DNA that persists in liver cells and can serve as a template for producing viral RNA. The therapy uses lipid nanoparticles to deliver messenger RNA encoding the ARCUS nuclease, with the aim of cutting and clearing this viral reservoir. Pregenomic RNA (pgRNA), which the study tracks, is a blood marker of cccDNA transcriptional activity and can provide clues as to whether the drug is acting through its intended mechanism.
ELIMINATE-B uses a dose-escalation design, with participants receiving repeat infusions at intervals of at least four weeks while on nucleos(t)ide analogue therapy. The primary endpoint is safety. The company's updated data, with a cutoff of September 28, 2026, covered 25 patients and 59 doses; the AASLD meeting abstract released at the same time listed 24 patients and 58 doses. The two documents do not cover exactly the same data, and all figures cannot be treated as belonging to the same analysis.
Among 12 patients with detectable pgRNA before treatment who met the evaluation criteria, 11 reached undetectable levels after treatment, including all 6 at the selected dose of 0.4 mg/kg. The presentation defined evaluable patients as those with at least 28 days of data after their first dose; another 3 patients who were positive at baseline had not yet been included in the evaluation. Thus, “all 6” refers to a specific analysis population, rather than all patients who received that dose.
The duration of the response provides another clue: the meeting abstract reported that pgRNA had remained undetectable for more than six months in 6 patients. In the first participant positive for hepatitis B e antigen (HBeAg), pgRNA fell from 5,750 copies per milliliter at baseline to undetectable levels after the second dose. This indicates that responses are not limited to HBeAg-negative patients, but a single positive case remains insufficient to infer efficacy across that population.
The liver biopsy data also require a clear distinction between what was measured. The press release described results from two patients as approximately 10-fold and 35-fold reductions in cccDNA, respectively. However, the meeting abstract explicitly referred to cccDNA-derived transcripts, and the presentation charts also labeled the measurements as transcripts. These findings support reduced transcriptional activity of the viral template, but cannot be directly equated with proportional removal of cccDNA from the liver, much less establish that the reservoir has been completely cleared.
On safety, the presentation disclosed that one patient who received 0.8 mg/kg early in the trial experienced myocardial ischemia judged to be treatment-related, as well as a possibly related intracerebral hemorrhage. Under the current infusion protocol, 8 patients in the 0.4 mg/kg group received a total of 15 doses, with no serious adverse events observed, although there was one case of delayed elevation in the liver enzymes ALT and AST. These small-scale data help guide dose selection for further development but remain insufficient to rule out less common or later-emerging risks.
The company expects to begin dosing in a global Phase 2 trial in the first quarter of 2027, evaluating PBGENE-HBV alone and in combination with an antisense oligonucleotide. The current results come from an early trial reported by the company, and patients remain on nucleos(t)ide analogues; undetectable pgRNA and sustained viral control after treatment withdrawal represent two different levels of evidence. Whether Phase 2 can cross that threshold will determine whether these biomarker changes can translate into practical value from a finite course of treatment.